Subtopic Deep Dive
Pancreatic Cancer Genomic Analyses
Research Guide
What is Pancreatic Cancer Genomic Analyses?
Pancreatic Cancer Genomic Analyses examines genomic mutations including KRAS, SMAD4, and TP53 in pancreatic ductal adenocarcinoma (PDAC) using whole-exome sequencing (WES) and single-cell RNA sequencing (scRNA-seq).
This subtopic profiles mutational landscapes and intra-tumoral heterogeneity in PDAC. Key studies include WES on 109 micro-dissected cases (Witkiewicz et al., 2015, 1135 citations) and whole-genome sequencing redefining PDAC mutations (Waddell et al., 2015, 2598 citations). scRNA-seq reveals malignant progression (Peng et al., 2019, 1346 citations). Over 10 provided papers span foundational genetics to recent analyses.
Why It Matters
Genomic analyses identify actionable alterations like KRAS mutations, enabling precision oncology in PDAC, which has a 3-5% 5-year survival rate (Hezel et al., 2006). WES defines therapeutic targets across 109 PDAC cases (Witkiewicz et al., 2015), while scRNA-seq uncovers heterogeneity for subtype-specific inhibitors (Peng et al., 2019). These insights guide NCCN guidelines for advanced disease management (Tempero et al., 2021) and support trials like larotrectinib for TRK fusions applicable to pancreatic contexts (Drilon et al., 2018).
Key Research Challenges
Mutational Heterogeneity
PDAC tumors show diverse KRAS, SMAD4, and TP53 alterations across cases, complicating uniform targeting. WES on 109 cases revealed genetic diversity (Witkiewicz et al., 2015). scRNA-seq highlights intra-tumoral variability (Peng et al., 2019).
Evolutionary Dynamics
Tumor progression involves dynamic mutation acquisition, as seen in whole-genome landscapes (Waddell et al., 2015). Foundational models show Kras-Ink4a/Arf cooperation in metastasis (Aguirre et al., 2003). Tracking clonal evolution remains challenging.
Actionable Variant Detection
Identifying therapeutically targetable mutations amid high background noise is difficult in advanced PDAC. Studies link DPC4/SMAD4 status to failure patterns (Iacobuzio-Donahue et al., 2009). Integrating WES with clinical outcomes needs refinement (Tempero et al., 2021).
Essential Papers
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo J.W.L. Aerts, Emmanuel Rios Velazquez, Ralph T. H. Leijenaar et al. · 2014 · Nature Communications · 4.9K citations
The 2019 WHO classification of tumours of the digestive system
Irıs D. Nagtegaal, Robert D. Odze, David S. Klimstra et al. · 2019 · Histopathology · 3.8K citations
Contains fulltext : 229796.pdf (Publisher’s version ) (Open Access)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell, Marina Pajic, Ann‐Marie Patch et al. · 2015 · Nature · 2.6K citations
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · 2018 · New England Journal of Medicine · 2.6K citations
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ...
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca et al. · 2020 · Nature Reviews Gastroenterology & Hepatology · 2.3K citations
Genetics and biology of pancreatic ductal adenocarcinoma
Aram F. Hezel, Alec C. Kimmelman, Ben Z. Stanger et al. · 2006 · Genes & Development · 1.6K citations
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States with a median survival of <6 mo and a dismal 5-yr survival rate of 3%–5%. The cancer’s le...
Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma
Junya Peng, Baofa Sun, Chuanyuan Chen et al. · 2019 · Cell Research · 1.3K citations
Reading Guide
Foundational Papers
Start with Hezel et al. (2006) for PDAC genetics basics and Aguirre et al. (2003) for Kras-driven metastasis models, as they establish mutational foundations cited in later WES works.
Recent Advances
Study Waddell et al. (2015) for mutational landscapes, Witkiewicz et al. (2015) for WES targets, and Peng et al. (2019) for scRNA-seq advances.
Core Methods
Core techniques: WES for exome-wide mutations (Witkiewicz et al., 2015), scRNA-seq for heterogeneity (Peng et al., 2019), whole-genome sequencing for landscapes (Waddell et al., 2015).
How PapersFlow Helps You Research Pancreatic Cancer Genomic Analyses
Discover & Search
PapersFlow's Research Agent uses searchPapers to query 'KRAS TP53 SMAD4 mutations PDAC WES' retrieving Waddell et al. (2015), then citationGraph maps co-citations to Witkiewicz et al. (2015), and findSimilarPapers expands to Peng et al. (2019) for scRNA-seq heterogeneity.
Analyze & Verify
Analysis Agent applies readPaperContent on Witkiewicz et al. (2015) to extract WES mutation frequencies, verifyResponse with CoVe cross-checks KRAS prevalence against Hezel et al. (2006), and runPythonAnalysis computes mutation co-occurrence stats from extracted data using pandas. GRADE grading scores evidence strength for TP53 alterations.
Synthesize & Write
Synthesis Agent detects gaps in KRAS inhibitor trials post-Waddell et al. (2015), flags contradictions between WES and scRNA-seq subtypes (Peng et al., 2019), while Writing Agent uses latexEditText for PDAC subtype tables, latexSyncCitations for 10+ papers, and exportMermaid diagrams evolutionary dynamics.
Use Cases
"Analyze KRAS mutation prevalence in PDAC from WES studies"
Research Agent → searchPapers 'KRAS WES PDAC' → Analysis Agent → readPaperContent (Witkiewicz 2015) + runPythonAnalysis (pandas mutation frequency plot) → CSV export of co-mutation stats.
"Draft LaTeX review on PDAC genomic subtypes with citations"
Synthesis Agent → gap detection (post-Waddell 2015) → Writing Agent → latexEditText (intro) → latexSyncCitations (Hezel 2006, Peng 2019) → latexCompile (full PDF review).
"Find code for scRNA-seq analysis in pancreatic cancer papers"
Research Agent → paperExtractUrls (Peng 2019) → Code Discovery → paperFindGithubRepo → githubRepoInspect (Seurat R scripts for heterogeneity) → Python sandbox test.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PDAC genomic papers: searchPapers → citationGraph → DeepScan 7-step verification → structured report with GRADE scores. Theorizer generates hypotheses on SMAD4-TP53 interactions: analyze Peng (2019) scRNA-seq + Waddell (2015) genomes → theory diagram via exportMermaid. DeepScan applies CoVe checkpoints to validate Witkiewicz (2015) therapeutic targets against NCCN guidelines (Tempero 2021).
Frequently Asked Questions
What defines Pancreatic Cancer Genomic Analyses?
It examines KRAS, SMAD4, TP53 mutations in PDAC via WES and scRNA-seq to identify actionable alterations and evolutionary dynamics (Waddell et al., 2015; Peng et al., 2019).
What are core methods?
Whole-exome sequencing profiles 109 PDAC cases (Witkiewicz et al., 2015); scRNA-seq reveals intra-tumoral heterogeneity (Peng et al., 2019); whole-genome sequencing redefines landscapes (Waddell et al., 2015).
What are key papers?
Foundational: Hezel et al. (2006, 1560 citations) on PDAC genetics; Waddell et al. (2015, 2598 citations) on whole genomes; recent: Peng et al. (2019, 1346 citations) on scRNA-seq.
What open problems exist?
Challenges include resolving heterogeneity for targeting (Peng et al., 2019), evolutionary tracking (Waddell et al., 2015), and actionable variant validation in advanced PDAC (Tempero et al., 2021).
Research Pancreatic and Hepatic Oncology Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pancreatic Cancer Genomic Analyses with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers